NEW YORK, September 20, 2021 / PRNewswire / – AIkido Pharma Inc. (Nasdaq: AIKI) (âAIkidoâ or the âCompanyâ) today announced that the Company has secured an initial equity stake in the tele-health company Kerna Health (https : //kernahealth.com).
Kerna Health is a growing momentum, next-generation digital health monitoring and virtual care company. The Company is rapidly developing a large backlog of revenue sharing contracts, typically executed with partners / clients such as multi-hospital chains and smaller hospitals, LTC (long-term care) companies, large medical practices, ACO and other major healthcare players, who are seeking better patient outcomes, significant untapped revenue and lower healthcare costs through such contracts, by integrating their large patient populations on the platform. -technological form of Kerna for remote monitoring of patients with chronic diseases. The Company’s order book for these executed contracts is already at $ 25 million shareable pro-forma revenue, and with additional ongoing contracts, could reach $ 50 million in the short term, and $ 400 million after that – evidence of a clear growth path.
Kerna uses advanced software and online technologies, combined with home health and physiology monitoring devices such as blood glucose meters, blood pressure cuffs, scales and more, to better manage chronic diseases, such as heart disease, diabetes and long-term wounds. .
The technology platform gathers daily readings safely transmitted by devices used by patients, at home, in long-term or transitional care facilities, or hospitals, and on the basis of programmed criteria sends alerts to a patient’s primary and specialist care providers, as well as to the patients themselves or their families.
In addition to monitoring physiological data associated with these diseases, Kerna’s platform also offers complementary health support services that utilize expert content and behavior change recommendations and initiatives, under the guidance of workers. social workers and other non-clinical professionals using relevant Kerna digital technologies. One example is the Behavioral Health Integration Program designed, paid for and recommended by CMS / Medicare. (https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/BehavioralHealthIntegration.pdf).
Anthony hayes, CEO of AIkido said, âAfter COVID, the use of telemedicine and digital health services, such as those provided by Kerna, has exploded. This is also evidenced by branded customers, the backlog of revenue contracts that the company incorporates. to be recognized as recurring revenue over the coming year for itself and its healthcare provider partners / customers, and through the growing pipeline of Kerna’s technology platform. We’re excited about Kerna’s future and happy to be a part of it, especially as their pull could lead to a potential IPO. This transaction fits perfectly with our growth strategy as we build on our momentum with a clear focus on monetization and liquidity events for our shareholders. In addition, we are in a number of advanced business development discussions that we aim to close in the near future. “
Knowledge of crystal, Chief Revenue Officer of Kerna, said: âFirst of all, we are honored and delighted to be associated with the team at Akido Pharma. In addition to the investment benefits, we believe that the health data accumulated by Kerna could also serve as the basis for a collaboration with AIkido. I am a business development and revenue professional working in the Medicare space for over 20 years for companies that we have grown quickly enough to multi-billion dollar outflows – even years ago when the space s. ‘is warmed up as it did. not comparable to current market enthusiasm, focus on digital health and remote patient monitoring, and customer demand for the online health monitoring technologies and services we have at Kerna. Market surge for Medicare remote patient monitoring solutions, on the one hand, and market pull by healthcare providers, on the other hand. Hospitals, long term care facilities and medical practices, Go Big u have generated additional income by becoming Kerna customers / partners, while delivering better health outcomes to their patients. The demand is such that we are already generating a backlog of annual patient monitoring revenue with those healthcare partners / clients who may qualify for a very short term Kerna IPO. “
About Akido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small molecule cancer therapies. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently developing an innovative therapeutic drug platform through strong partnerships with institutions of world-renowned teaching, including The University of Texas at Austin and University of Maryland in Baltimore. Our diverse portfolio of therapeutic products includes therapies for pancreatic cancer and prostate cancer. We are constantly looking to expand our pipeline to address unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that could potentially inhibit the replication of several viruses, including influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebola virus and Marburg virus. .
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Words such as “may”, “could”, “will”, “should”, “believe”, “expect”, “anticipate”, “estimate”, “continue”, “predict”, “foresee” , âplanâ, âplanâ, âintentionâ or similar expressions, or statements regarding current intention, belief or expectations, are forward-looking statements. Although the Company believes that these forward-looking statements are reasonable, we should not place undue reliance on these forward-looking statements, which are based on information available to us as of the date of this press release. These forward-looking statements are based on current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in documents filed by the Company with the SEC, without being limited to factors of risk related to its activities contained therein. Thus, the actual results could be materially different. The Company expressly disclaims any obligation to update or modify statements, whether as a result of new information, future events or otherwise, except as required by law.
Brett maas, Management partner
Telephone: (646) 536-7331
E-mail: [emailÂ protected]
AIkido Pharma Inc.
E-mail: [emailÂ protected]
Knowledge of crystal, director of recipes
E-mail: [emailÂ protected]
SOURCE AIkido Pharma Inc.